Glucose Homeostasis

Glucose Homeostasis

Glucose homeostasis refers to the tightly regulated system that maintains blood glucose levels within a physiological range of approximately 70–140 mg/dL throughout the day. This regulation involves a complex interplay between insulin secretion from pancreatic beta cells, glucagon release from alpha cells, hepatic glucose production, peripheral glucose uptake, and incretin hormone signaling from the gut. When this system functions properly, blood glucose rises modestly after meals and returns to baseline within a few hours, ensuring a steady energy supply to glucose-dependent tissues such as the brain.

Disruption of glucose homeostasis is the hallmark of type 2 diabetes and prediabetes. In these conditions, insulin resistance in muscle, liver, and adipose tissue reduces the effectiveness of insulin-mediated glucose disposal, while progressive beta-cell dysfunction impairs the compensatory insulin response. Over time, fasting and postprandial glucose levels rise, leading to chronic hyperglycemia and its associated complications, including cardiovascular disease, nephropathy, neuropathy, and retinopathy.

Retatrutide’s triple agonist mechanism targets glucose homeostasis through multiple complementary pathways. GLP-1 receptor activation stimulates glucose-dependent insulin secretion and suppresses inappropriate glucagon release, while GIP receptor agonism further potentiates insulin secretion and may improve beta-cell function. Glucagon receptor activation enhances hepatic energy expenditure and lipid oxidation, indirectly improving insulin sensitivity. In Phase 2 trials, retatrutide demonstrated HbA1c reductions of up to 2.02% in participants with type 2 diabetes, reflecting substantial improvements in overall glucose homeostasis.